Discontinuation of nilotinib treatment in a patient with chronic myelogenous leukemia and thrombocytopenia induced by imatinib
Abstract
Treatment of chronic myelogenous leukemia (CML) with BCR-ABL1 tyrosine kinase inhibitors (TKI) significantly changed the course of this disease and had a positive effect on prognosis. Thanks to targeted therapy, CML has transformed from an incurable disease with limited treatment options into a more indolent disease with survival comparable to that of the general population. Moreover, there is a certain group of patients who can be permanently discontinued from treatment. This is especially important in the case of TKI-related side effects, which may reduce the patient’s quality of life. In this article we present a case report of CML patient who developed immune thrombocytopenia after imatinib treatment. In the second-line nilotinib was used. Despite dose reduction (because of decreased platelet level) treatment with nilotinib allowed for deepening of the molecular response. Thanks to this, the patient turned out to be a suitable candidate for treatment discontinuation after a few years.
Keywords: chronic myelogenous leukemiaBCR-ABL1 tyrosine kinase inhibitorstreatment discontinuation
References
- Goldman JM. Chronic myeloid leukemia: a historical perspective. Semin Hematol. 2010; 47(4): 302–311.
- Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017; 35(3): 298–305.
- Campiotti L, Suter MB, Guasti L, et al. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis. Eur J Cancer. 2017; 77: 48–56.
- Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018; 19(6): 747–757.
- Sneed TB, Kantarjian HM, Talpaz M, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer. 2004; 100(1): 116–121.
- Deininger MWN, O'Brien SG, Ford JM, et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003; 21(8): 1637–1647.
- Fachi MM, Tonin FS, Leonart LP, et al. Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta-analysis. Br J Clin Pharmacol. 2019; 85(10): 2280–2291.
- Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2(5): 561–566.
- Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347(7): 472–480.
- Saglio G, Kim DW, Issaragrisil S, et al. ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362(24): 2251–2259.
- Wei G, Rafiyath S, Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol. 2010; 3: 47.
- Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4): 966–984.
- Program Lekowy dla Przewlekłej Białaczki Szpikowej [Program lekowy. Leczenie przewlekłej białaczki szpikowej?]. https://hematoonkologia.pl/upload/programy-lekowe/B.14-leczenie-pbsz-od-07-2019.pdf (September 30, 2020).
